ERBB2 and breast cancer: Hergueta-Redondo et al. found that GSDMB-2 induces invasion, tumor progression, and metastasis in MCF7 breast cancer cells, and overexpression of GSDMB predicts low responsiveness to erb-b2 receptor tyrosine kinase 2 (HER2)-targeted therapy in HER2-positive breast cancer [85].